Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline

British Journal of Clinical Pharmacology

Volumn 65, Issue 3, 2008, Pages 347-354

  Davies, Benjamin J ^a,b   Herbert, Megan K ^a   Coller, Janet K ^b   Somogyi, Andrew A ^b   Milne, Robert W ^c   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

CYP2D6; Enantioselective; Perhexiline; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMITRIPTYLINE; CLOPIDOGREL; DILTIAZEM; FLUTICASONE; FUROSEMIDE; GLIMEPIRIDE; INSULIN; IPRATROPIUM BROMIDE; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; METFORMIN; METOPROLOL; MORPHINE; PANTOPRAZOLE; PARACETAMOL; PAROXETINE; PERHEXILINE MALEATE; PERINDOPRIL; PREDNISOLONE; SALBUTAMOL; SALMETEROL; SIMVASTATIN; SPIRONOLACTONE; THEOPHYLLINE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

AGED; ANGINA PECTORIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; STEADY STATE;

AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PERHEXILINE; POLYMORPHISM, GENETIC; STEREOISOMERISM; TIME FACTORS;

EID: 39849096274     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03015.x     Document Type: Article

References (28)

1. Armstrong ML. A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. Postgrad Med J 1973 49 (Suppl. 3 108 11.
2. Opie LH. Drugs and the heart. III. Calcium antagonists. Lancet 1980 1 : 806 10.
3. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004 25 : 634 41.
4. Horowitz JD, Sia STB, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate for severe angina pectoris - correlations with pharmacokinetics. Int J Cardiol 1986 13 : 219 29.
5. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, Hartley LH, Smith TW, Antman EM. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990 81 : 1260 70.
6. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005 112 : 3280 8.
7. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996 52 : 273 80.
8. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Malloy CR. Direct evidence that perhexiline modifies myocardial substrate utilisation from fatty acids to lactate. J Cardiovasc Pharmacol 1995 25 : 469 72.
9. Unger SA, Kennedy JA, McFadden-Lewis K, Minerds K, Murphy GA, Horowitz JD. Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. J Cardiovasc Pharmacol 2005 46 : 849 55.
10. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984 25 : 1057 64.
11. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. BMJ 1982 284 : 295 9.
12. Sallustio BC, Westley IC, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady state dose. Br J Clin Pharmacol 2002 54 : 107 14.
13. Barclay ML, Sawyers SM, Begg EJ, Zhang M, Roberts RL, Kennedy MA, Elliott JM. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003 13 : 627 32.
14. Davies BJ, Coller JK, James HM, Gillis D, Somogyi AA, Horowitz JD, Morris RG, Sallustio BC. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. Br J Clin Pharmacol 2004 57 : 456 63.
15. Davies BJ, Coller JK, James HM, Somogyi AA, Horowitz JD, Sallustio BC. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. Br J Clin Pharmacol 2006 61 : 321 5.
16. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 23 37.
17. Inglis SC, Herbert MK, Davies BJ, Coller JK, James HM, Horowitz JD, Morris RG, Milne RW, Somogyi AA, Sallustio BC. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenet Genomics 2007 17 : 305 12.
18. Davies BJ, Coller JK, Somogyi AA, Milne RW, Sallustio BC. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 2007 35 : 128 38.
19. Davies BJ, Herbert MK, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. J Chromatogr B 2006 843 : 302 9.
20. James HM, Coller JK, Gillis D, Bahnisch J, Sallustio BC, Somogyi AA. A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. Int J Clin Pharmacol Ther 2004 42 : 719 23.
21. Davies BJ, Herbert MK, Culbert JA, Pyke SM, Coller JK, Somogyi AA, Milne RW, Sallustio BC. Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B 2006 832 : 114 20.
22. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992 81 : 309 12.
23. Alderman CP, Hundertmark JD, Soetratma TW. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust NZ J Psychiatry 1997 31 : 601 3.
24. Nyfort-Hansen K. Perhexiline toxicity related to citalopram use. Med J Aust 2002 176 : 560 1.
25. Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000 40 : 58 66.
26. Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978 14 : 195 201.
27. Amoah AG, Gould BJ, Parke DV, Lockhart JD. Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 1986 16 : 63 8.
28. Cooper RG, Evans DA, Price AH. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 1987 32 : 569 76.